CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Novartis Adr Repsg 1 - USD - NVS CFD

94.30
0.88%
Market Trading Hours* (UTC) Opens on Tuesday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.16
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Novartis AG ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 93.48
Open* 94.19
1-Year Change* -3.75%
Day's Range* 94.16 - 94.89
52 wk Range 75.68-108.41
Average Volume (10 days) 1.37M
Average Volume (3 months) 31.52M
Market Cap 245.41B
P/E Ratio 30.64
Shares Outstanding 2.06B
Revenue 47.89B
EPS 3.53
Dividend (Yield %) 3.23864
Beta 0.56
Next Earnings Date Jan 31, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 12, 2024 93.48 -1.37 -1.44% 94.85 95.01 93.30
Apr 11, 2024 94.29 -0.54 -0.57% 94.83 94.83 93.64
Apr 10, 2024 94.30 -0.18 -0.19% 94.48 94.60 93.96
Apr 9, 2024 95.72 0.11 0.12% 95.61 95.84 95.30
Apr 8, 2024 95.42 -0.21 -0.22% 95.63 96.08 95.18
Apr 5, 2024 95.71 0.47 0.49% 95.24 95.87 94.96
Apr 4, 2024 96.83 -0.18 -0.19% 97.01 98.13 96.47
Apr 3, 2024 94.30 -0.14 -0.15% 94.44 94.82 94.06
Apr 2, 2024 94.35 -0.14 -0.15% 94.49 94.54 93.84
Apr 1, 2024 95.78 -1.07 -1.10% 96.85 96.92 95.33
Mar 28, 2024 96.48 0.31 0.32% 96.17 97.14 96.08
Mar 27, 2024 95.83 0.36 0.38% 95.47 95.84 95.20
Mar 26, 2024 95.20 -0.27 -0.28% 95.47 95.50 95.00
Mar 25, 2024 95.70 -0.38 -0.40% 96.08 96.23 95.69
Mar 22, 2024 96.15 0.13 0.14% 96.02 96.45 95.83
Mar 21, 2024 95.99 -0.36 -0.37% 96.35 96.73 95.99
Mar 20, 2024 96.01 0.31 0.32% 95.70 96.08 95.14
Mar 19, 2024 96.25 0.16 0.17% 96.09 96.44 95.81
Mar 18, 2024 95.87 -0.95 -0.98% 96.82 96.94 95.83
Mar 15, 2024 97.23 -0.83 -0.85% 98.06 98.25 96.55

Novartis Adr Repsg 1 - USD Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 51742 52877 49898 48624 46017
Revenue 51742 52877 49898 48624 46017
Cost of Revenue, Total 14998 15435 14400 13930 13555
Gross Profit 36744 37442 35498 34694 32462
Total Operating Expense 42545 41188 39746 39538 31824
Selling/General/Admin. Expenses, Total 14190 14815 14093 14319 13690
Research & Development 9088 9041 8484 8386 8154
Depreciation / Amortization 158 109 64 50 179
Unusual Expense (Income) 3402 1173 2503 2284 -4309
Other Operating Expenses, Total 449 653 538 607 549
Operating Income 9197 11689 10152 9086 14193
Interest Income (Expense), Net Non-Operating -543 14628 -146 -36 -5
Other, Net -283 -180 -128 -110 -93
Net Income Before Taxes 8371 26137 9878 8940 14095
Net Income After Taxes 6955 24018 8071 7147 12800
Minority Interest 0 3 1 -5 -3
Net Income Before Extra. Items 6955 24021 8072 7142 12797
Net Income 6955 24021 8072 11732 12611
Income Available to Common Excl. Extra. Items 6955 24021 8072 7142 12797
Income Available to Common Incl. Extra. Items 6955 24021 8072 11732 12611
Dilution Adjustment
Diluted Net Income 6955 24021 8072 11732 12611
Diluted Weighted Average Shares 2197 2260 2296 2319 2344
Diluted EPS Excluding Extraordinary Items 3.16568 10.6288 3.51568 3.07978 5.45947
Dividends per Share - Common Stock Primary Issue 3.46171 3.19907 3.08737 2.83413 2.93645
Diluted Normalized EPS 4.47075 11.1183 4.40641 3.86715 3.79006
Total Extraordinary Items 4590 -186
Interest Expense (Income) - Net Operating 260 -38 -336 -38 6
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total revenue 12092 22792 13208 13001 10783
Revenue 12092 22792 13208 13001 10783
Cost of Revenue, Total 3089 5944 3829 3837 2874
Gross Profit 9003 16848 9379 9164 7909
Total Operating Expense 10330 17367 10352 11052 8957
Selling/General/Admin. Expenses, Total 3093 5952 3401 3699 2936
Research & Development 2187 4182 2272 2318 2542
Depreciation / Amortization 169 198 153 42
Interest Expense (Income) - Net Operating -6 69 46 -28 90
Unusual Expense (Income) 1751 648 298 1145 302
Other Operating Expenses, Total 47 374 353 39 213
Operating Income 1762 5425 2856 1949 1826
Interest Income (Expense), Net Non-Operating -225 -420 -212 -222 -211
Other, Net 15 189 96 14 -28
Net Income Before Taxes 1552 5194 2740 1741 1587
Net Income After Taxes 1513 4421 2294 1466 1330
Minority Interest -2 -2 -1 0 -2
Net Income Before Extra. Items 1511 4419 2293 1466 1328
Net Income 1761 4609 2293 1466 1573
Income Available to Common Excl. Extra. Items 1511 4419 2293 1466 1328
Income Available to Common Incl. Extra. Items 1761 4609 2293 1466 1573
Diluted Net Income 1761 4609 2293 1466 1573
Diluted Weighted Average Shares 2075 2086.5 2120 2158 2180
Diluted EPS Excluding Extraordinary Items 0.72819 2.1179 1.0816 0.67933 0.60917
Dividends per Share - Common Stock Primary Issue 0 0 0 3.46171 0
Diluted Normalized EPS 1.55084 2.38225 1.20956 1.14055 0.72527
Total Extraordinary Items 250 190 245
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 36910 45718 29673 29504 35563
Cash and Short Term Investments 18726 28113 11293 11234 15718
Cash 2877 3396 3750 3247 3121
Cash & Equivalents 4640 9011 5908 7865 10150
Short Term Investments 11209 15706 1635 122 2447
Total Receivables, Net 9894 9621 10036 10337 11036
Accounts Receivable - Trade, Net 8066 8005 8217 8301 8739
Total Inventory 7175 6666 7131 5982 6956
Prepaid Expenses 911 1102 943 898 812
Other Current Assets, Total 204 216 270 1053 1041
Total Assets 117453 131795 127778 118370 145563
Property/Plant/Equipment, Total - Net 12195 13106 13939 13746 15696
Property/Plant/Equipment, Total - Gross 26304 28708 29894 28676 34028
Accumulated Depreciation, Total -14109 -15602 -15955 -14930 -18332
Goodwill, Net 29301 29595 29999 26524 35294
Intangibles, Net 31644 34182 36809 28787 38719
Long Term Investments 1606 2268 11611 10538 9789
Note Receivable - Long Term 948 973 922 624 908
Other Long Term Assets, Total 4849 5953 4825 8647 9594
Total Current Liabilities 28656 30208 33059 28264 29607
Accounts Payable 5146 5553 5403 5424 5556
Accrued Expenses 5334 5100 5336 5058 5105
Notes Payable/Short Term Debt 3635 3606 7319 4844 6430
Current Port. of LT Debt/Capital Leases 2492 2896 2558 2248 3190
Other Current Liabilities, Total 12049 13053 12443 10690 9326
Total Liabilities 58111 64140 71180 62896 66949
Total Long Term Debt 21782 24523 27978 22056 22470
Long Term Debt 20244 22902 26259 20353 22470
Deferred Income Tax 2686 3070 3141 5867 7475
Minority Interest 81 167 68 77 78
Other Liabilities, Total 4906 6172 6934 6632 7319
Total Equity 59342 67655 56598 55474 78614
Common Stock 890 901 913 936 944
Retained Earnings (Accumulated Deficit) 63540 70989 57157 59274 82191
Treasury Stock - Common -92 -48 -53 -80 -69
Unrealized Gain (Loss) -198 206
Other Equity, Total -4798 -4187 -1419 -4656 -4658
Total Liabilities & Shareholders’ Equity 117453 131795 127778 118370 145563
Total Common Shares Outstanding 2119.61 2234.94 2256.82 2265.01 2311.17
Capital Lease Obligations 1538 1621 1719 1703
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 45660 33493 32114 36910 36954
Cash and Short Term Investments 12695 11174 12260 18930 19103
Cash & Equivalents 12405 10885 12000 7517 8726
Short Term Investments 290 289 260 11413 10377
Total Receivables, Net 7099 9543 9183 8334 8680
Accounts Receivable - Trade, Net 6819 9195 8916 8066 8422
Total Inventory 5610 8228 7886 7175 6779
Other Current Assets, Total 20256 4548 2785 2471 2392
Total Assets 112697 110979 112241 117453 118464
Property/Plant/Equipment, Total - Net 10344 12277 12348 12195 11731
Goodwill, Net 23416 29522 29481 29301 28668
Intangibles, Net 26418 28003 30451 31644 31888
Long Term Investments 2122 2433 2555 2554 2491
Other Long Term Assets, Total 4737 5251 5292 4849 6732
Total Current Liabilities 48393 31909 30549 28656 28160
Accounts Payable 3870 5350 5426 5146 4693
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 5602 8496 7166 6127 7204
Other Current Liabilities, Total 38921 18063 17957 17383 16263
Total Liabilities 74533 59132 60182 58111 57644
Total Long Term Debt 19521 19804 21985 21782 21235
Long Term Debt 18068 18259 20396 20244 19732
Capital Lease Obligations 1453 1545 1589 1538 1503
Deferred Income Tax 2457 2526 2727 2686 2719
Minority Interest 81 84 83 81 78
Other Liabilities, Total 4081 4809 4838 4906 5452
Total Equity 38164 51847 52059 59342 60820
Common Stock 825 842 842 890 890
Retained Earnings (Accumulated Deficit) 37371 51057 51253 58544 60000
Treasury Stock - Common -32 -52 -36 -92 -70
Total Liabilities & Shareholders’ Equity 112697 110979 112241 117453 118464
Total Common Shares Outstanding 2055.46 2068.26 2097.4 2119.61 2150.98
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 6955 24018 8071 7147 12800
Cash From Operating Activities 14236 15071 13650 13625 14272
Cash From Operating Activities 1873 1807 2088 1852 1783
Amortization 5308 4306 4376 3974 3428
Non-Cash Items 4404 -11714 3842 3369 -2315
Cash Taxes Paid 1975 2342 1833 1876 1506
Cash Interest Paid 696 664 703 793 816
Changes in Working Capital -4304 -3346 -4727 -2717 -1424
Cash From Investing Activities 1468 4208 -13182 -2226 -5591
Capital Expenditures -2671 -2971 -2585 -2257 -2648
Other Investing Cash Flow Items, Total 4139 7179 -10597 31 -2943
Cash From Financing Activities -20562 -16264 -2208 -13627 -4244
Financing Cash Flow Items 55 94 -199 3307 -119
Total Cash Dividends Paid -7506 -7368 -6987 -6645 -6966
Issuance (Retirement) of Stock, Net -10552 -3004 -2094 -5332 -1336
Issuance (Retirement) of Debt, Net -2559 -5986 7072 -4957 4177
Foreign Exchange Effects -32 -266 286 69 -26
Net Change in Cash -4890 2749 -1454 -2159 4411
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 2294 6955 5489 3914 2219
Cash From Operating Activities 2957 14236 10125 5404 1649
Cash From Operating Activities 377 7181 5233 3207 1405
Amortization 1619
Non-Cash Items 1085 4404 3417 2164 918
Cash Taxes Paid 348 1975 1559 1239 633
Cash Interest Paid 123 696 475 308 110
Changes in Working Capital -2418 -4304 -4014 -3881 -2893
Cash From Investing Activities 10621 1468 2935 -2263 9365
Capital Expenditures -470 -2671 -2024 -1442 -859
Other Investing Cash Flow Items, Total 11091 4139 4959 -821 10224
Cash From Financing Activities -9202 -20562 -16568 -11830 -9528
Financing Cash Flow Items -169 55 99 97 22
Total Cash Dividends Paid -7255 -7506 -7506 -7506 -7506
Issuance (Retirement) of Stock, Net -2727 -10552 -7874 -5156 -2448
Issuance (Retirement) of Debt, Net 949 -2559 -1287 735 404
Foreign Exchange Effects 107 -32 -173 -93 -41
Net Change in Cash 4483 -4890 -3681 -8782 1445

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Novartis ADR Company profile

Novartis (NVS) provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. Novartis Group companies employ approximately 122,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. The company has been honoured and received numerous awards for progress in research and development, their working environment, and their corporate responsibility activities. Novartis shares are listed and traded on the SIX Swiss Exchange (symbol “NOVN”) as well as on the New York Stock Exchange in the form of ADR (symbol “NVS”). Get all the latest on Novartis Repsg (NVS) share price at Capital.com.
Industry: Pharmaceuticals (NEC)

Lichtstrasse 35
BASEL
BASEL-STADT 4056
CH

Income Statement

  • Annual
  • Quarterly

News

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

People also watch

US100

17,711.20 Price
-1.630% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

ETH/USD

3,112.32 Price
+1.470% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

BTC/USD

63,756.30 Price
-0.260% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Gold

2,381.62 Price
+1.660% 1D Chg, %
Long position overnight fee -0.0187%
Short position overnight fee 0.0105%
Overnight fee time 21:00 (UTC)
Spread 0.50

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading